FindTrial
Sign In

Clinical Studies on the Efficacy of IgA Nephropathy Treatment

Clinical Research on Drug Efficacy-Related Genomes (NR3C1; AGTR1, etc.) and Potential Circulating Target Proteins (Gd-IgA1; NFkB1, etc.) in Progressive IgA Nephropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117421
Enrollment
Unknown
Registered
2026-01-23
Start date
2025-08-07
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary IgA Nephropathy

Interventions

Valid group:NA
Invalid group:NA

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Ages = 18; 2. 24-h urine total protein=0.5g (before treatment); 3. eGFR=30ml/min.1.73m^2; 4. primary IgA nephropathy diagonsed by kidney biopsy.

Exclusion criteria

Exclusion criteria: 1. SLE; 2. Henoch-Schönlein purpura nephritis; 3. Chronic liver disease.

Design outcomes

Primary

MeasureTime frame
Gd-IgA1;NFKB1;AGTR1 Gene Encoding (A1166C);SNPs in the NR3C1 Encoding Gene;—

Countries

China

Contacts

Public ContactLi Zhan

Beijing Hospital

lizhan98142@hotmail.com+86 10 8513 3880

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026